Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced its pa...
High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...
F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that Nancy...
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...
Biopharmaceutical company Denali Therapeutics ([[DNLI]] +7.5%) highlights pipeline updates and 2021 milestones ahead of the coveted annual J.P. Morgan Healthcare Conference lined up next week.Phase 1b study of LRRK2 inhibitor, DNL151 (BIIB122), collaborating with Biogen, in Parkinson’s...
Late-breaker presentation on 12-week data from Cohort A in Phase 1/2 study of DNL310 (ETV:IDS) in Hunter syndrome (MPS II) to be held at WORLD Symposium on February 12th Following previously announced data on CSF GAG reduction with DNL310 and achievement of biomarker proof-of-...
Denali has a market cap of $10bn after Biogen's $1bn deal with it. Its assets are in the early stages. While 3 major biopharma companies have gambled on Denali, the stakes are too high right now. For further details see: Denali: A $10B Early Stage Biotech Targeting Parki...
A funny thing happened on the way to the Christmas holidays and the end of the final quarter of 2020. All of a sudden, out of the blue, shares of multiple unrelated stocks began to sell off. As the final hour of trading got under way Wednesday, shares of database software company Mong...
Healthcare experienced a significant risk-diminishing event as the Affordable Care Act appears more secure. Biotechs continue to lead healthcare as vaccine progress and key approvals draw significant attention. Drug pricing remains a dormant issue for now although key moves last w...
News, Short Squeeze, Breakout and More Instantly...
Denali Therapeutics Inc. Company Name:
DNLI Stock Symbol:
NASDAQ Market:
Denali Therapeutics Inc. Website:
2024-07-10 22:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potentia...
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...